Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease

Autor: Mauro Mastronardi, Margherita Curlo, Elisabetta Cavalcanti, Osvaldo Burattini, Renato Cuppone, Romina Tauro, Stefania De Santis, Grazia Serino, Pasqua Letizia Pesole, Elisa Stasi, Maria Lucia Caruso, Rossella Donghia, Vito Guerra, Pietro Giorgio, Marcello Chieppa
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Frontiers in Medicine, Vol 6 (2019)
Druh dokumentu: article
ISSN: 2296-858X
DOI: 10.3389/fmed.2019.00234
Popis: Biological intervention for Crohn's Disease (CDs) patients, mainly using anti-TNF antibodies, is often an efficient therapeutic solution. Nonetheless, data defining the administration timing to maximize the chances of clinical remission are lacking. The objective of this “real-life” retrospective study was to evaluate if early Adalimumab (ADA) administration (12 months) (p < 0.001); mucosal healing was observed in 53.75% of the early vs. 20.78% of the late (p < 0.001). Dose escalation was required for 30.00% of the early vs. 66.23% of the late (
Databáze: Directory of Open Access Journals